IN2014DN09782A - - Google Patents

Info

Publication number: IN2014DN09782A
Authority: IN; India
Prior art keywords: glp; analogues; gly2; gastro; ameliorating
Prior art date: 2012-05-03

Application number

Other languages

English (en)

Inventor

Rasmus Just

Kirsten Lindegaard Bovbjerg

Ditte Riber

Wayne Shaun Russell

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-03

Filing date

2014-11-19

Publication date

2015-07-31

2014-11-19 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2015-07-31 Publication of IN2014DN09782A publication Critical patent/IN2014DN09782A/en

Links

230000000694 effects Effects 0.000 abstract 2
101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 abstract 1
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 abstract 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Zoology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Insects & Arthropods (AREA)
Hematology (AREA)
Obesity (AREA)
Biotechnology (AREA)
Reproductive Health (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)

IN9782DEN2014 2012-05-03 2014-11-19 IN2014DN09782A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261642447P	2012-05-03	2012-05-03
US201361785852P	2013-03-14	2013-03-14
PCT/EP2013/059320 WO2013164484A1 (fr)	2012-05-03	2013-05-03	Analogues du glucagon-like peptide 2 (glp-2)

Publications (1)

Publication Number	Publication Date
IN2014DN09782A true IN2014DN09782A (fr)	2015-07-31

Family

ID=48428462

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN9782DEN2014 IN2014DN09782A (fr)	2012-05-03	2014-11-19

Country Status (13)

Country	Link
US (3)	US9453064B2 (fr)
EP (1)	EP2844670B1 (fr)
JP (1)	JP6298044B2 (fr)
KR (1)	KR20150006052A (fr)
CN (1)	CN104540850B (fr)
AU (1)	AU2013255752B2 (fr)
BR (1)	BR112014027345A2 (fr)
CA (1)	CA2872315A1 (fr)
EA (1)	EA028929B1 (fr)
IN (1)	IN2014DN09782A (fr)
MX (1)	MX356958B (fr)
TR (1)	TR201802689T4 (fr)
WO (1)	WO2013164484A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101527233B1 (ko)	2006-11-08	2015-06-08	질랜드 파마 에이/에스	선택적인 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
CA2872315A1 (fr)	2012-05-03	2013-11-07	Zealand Pharma A/S	Analogues du glucagon-like peptide 2 (glp-2)
CN109456400A (zh)	2012-07-23	2019-03-12	西兰制药公司	胰高血糖素类似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
RS57632B1 (sr)	2013-10-17	2018-11-30	Zealand Pharma As	Acilovani analozi glukagona
CN105849122B (zh)	2013-11-06	2021-04-30	西兰制药公司	Gip-glp-1双重激动剂化合物及方法
JP2017503474A (ja)	2013-11-06	2017-02-02	ジーランドファーマアクティーゼルスカブ	グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (fr)	2013-12-13	2018-02-07	Sanofi	Agonistes doubles du récepteur glp-1/gip
WO2015086728A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
TW201609800A (zh) *	2013-12-13	2016-03-16	賽諾菲公司	做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI705973B (zh)	2014-10-29	2020-10-01	丹麥商西蘭製藥公司	Ｇｉｐ促效劑化合物及方法
JP2017537894A (ja) *	2014-10-31	2017-12-21	グブラエーピーエス	Ｇｌｐ−１ｒおよびｇｌｐ−２ｒ二重アゴニスト活性を有する組成物及びペプチド
PL3283507T3 (pl)	2015-04-16	2020-05-18	Zealand Pharma A/S	Acylowany analog glukagonu
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP7026044B2 (ja)	2015-12-23	2022-02-25	ザ・ジョンズ・ホプキンス・ユニバーシティー	神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ－１ｒアゴニスト
JP6700150B2 (ja) *	2016-10-03	2020-05-27	東京エレクトロン株式会社	パーティクル捕集装置、パーティクル捕集方法、およびパーティクル捕集システム
RU2756011C2 (ru) *	2016-12-09	2021-09-24	Зилэнд Фарма А/С	Glp-1/glp-2 двойные агонисты
WO2018104558A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
WO2018103868A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
WO2018104559A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2
EP3551651B1 (fr)	2016-12-09	2024-03-06	Zealand Pharma A/S	Doubles agonistes glp-1/glp-2 acylés
ES2894629T3 (es) *	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
GB201710822D0 (en) *	2017-07-05	2017-08-16	Zealand Pharma As	Methods and medical uses relating to the treatment of hypoglycaemia
AU2018360744A1 (en)	2017-11-06	2020-05-07	Takeda Pharmaceutical Company Limited	GLP-2 analogs and peptibodies for administration before during, or after surgery
WO2020020904A1 (fr)	2018-07-23	2020-01-30	Zealand Pharma A/S	Utilisations thérapeutiques d'agonistes de glp-2
US20200254065A1 (en)	2019-02-11	2020-08-13	Opko Biologics Ltd.	Long-acting glp-2 analogs
JP7580403B2 (ja)	2019-06-14	2024-11-11	ジーランド・ファーマ・ア／エス	Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
WO2021071837A1 (fr)	2019-10-07	2021-04-15	Kallyope, Inc.	Agonistes de gpr119
CN111329995B (zh) *	2020-02-18	2022-11-11	河南中医药大学	Glp-2类似物在制备防治pd药物中的应用及防治pd的药物
BR112022017039A2 (pt)	2020-02-28	2022-11-16	Kallyope Inc	Agonistas de gpr40
CN115697375A (zh) *	2020-04-03	2023-02-03	韩美药品株式会社	预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
JP2023526625A (ja)	2020-05-19	2023-06-22	キャリーオペ，インク．	Ａｍｐｋアクチベーター
KR20230038187A (ko)	2020-06-09	2023-03-17	벡티브바이오 에이지	아프라글루타이드의 제조, 제형화 및 투여
CN116390925A (zh)	2020-06-26	2023-07-04	卡尔优普公司	Ampk活化剂
JP2025530325A (ja)	2022-09-19	2025-09-11	ジーランドファーマエー／エス	組合せ療法
CN116478269A (zh) *	2023-04-28	2023-07-25	成都奥达生物科技有限公司	一种长效替度鲁肽化合物
CN118146350B (zh) *	2024-03-13	2024-10-22	北京泽勤生物医药有限公司	Glp-2肽类似物的制备方法及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
JP2961045B2 (ja)	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
US6184208B1 (en)	1994-06-29	2001-02-06	Immunotech Developments Inc.	Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5789379A (en)	1995-04-14	1998-08-04	Allelix Biopharmaceutical Inc.	Glucagon-like peptide-2 analogs
US5912229A (en)	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
BR9707807A (pt)	1996-03-01	1999-07-27	Novo Nordisk As	Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo
JP4148994B2 (ja)	1996-04-12	2008-09-10	１１４９３３６オンタリオインコーポレイテッド	グルカゴン様ペプチド―２アナログ
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
ES2283025T3 (es)	1996-08-30	2007-10-16	Novo Nordisk A/S	Derivados de glp-1.1.
US20020025933A1 (en)	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
DK0929567T3 (da)	1996-09-09	2005-06-27	Zealand Pharma As	Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese
US5952301A (en)	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
CA2236519C (fr)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methodes pour ameliorer le fonctionnement du gros intestin
JP4699576B2 (ja)	1997-05-16	2011-06-15	１１４９３３６オンタリオインコーポレーテッド	胃腸管上部の機能を強化する方法
US6051557A (en)	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
DE04029691T1 (de)	1998-02-02	2007-11-08	Trustees Of Tufts College, Medford	Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
CA2321026A1 (fr)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Conjugues peptidiques pharmacologiquement actifs ayant une tendance reduite a l'hydrolyse enzymatique
AU7421598A (en)	1998-05-11	1999-11-29	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
CN1344248A (zh)	1999-03-17	2002-04-10	诺沃挪第克公司	肽的酰化方法和新酰化剂
EP1076066A1 (fr)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides abaissant le taux de glucose sanguin
AU2020501A (en)	1999-12-08	2001-06-18	1149336 Ontario Inc.	Chemotherapy treatment
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
DK1326630T3 (da)	2000-09-18	2008-09-15	Sanos Bioscience As	Anvendelse af GLP-2-peptider
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002066062A2 (fr)	2001-02-01	2002-08-29	Drucker Daniel J	Renforcement de l'activite de glp-2
CA2436399A1 (fr)	2001-02-16	2002-08-29	Conjuchem Inc.	Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
JP2005506956A (ja)	2001-06-01	2005-03-10	イーライ・リリー・アンド・カンパニー	長時間作用性ｇｌｐ−１製剤
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
MXPA05003797A (es) *	2002-10-14	2005-06-08	Novo Nordisk As	Variantes de peptido-2 tipo glucagon.
CN1705681A (zh) *	2002-10-14	2005-12-07	诺沃挪第克公司	Glp－2化合物、制剂及其用途
JP4949838B2 (ja)	2003-09-19	2012-06-13	ノヴォノルディスクアー／エス	新規ｇｌｐ−１誘導体
WO2005082404A2 (fr) *	2004-02-27	2005-09-09	Novo Nordisk A/S	Composes de glp-2, formulations et utilisations de ceux-ci
CA2585482C (fr)	2004-11-01	2018-01-02	Nps Allelix Corp.	Traitement de patients atteints du syndrome de l'intestin court avec colon en continuite
CA2607150C (fr)	2005-05-04	2014-08-05	Bjarne Due Larsen	Analogues du glp-2 (glucagon-like-peptide-2)
KR101527233B1 (ko)	2006-11-08	2015-06-08	질랜드 파마 에이/에스	선택적인 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
MX2011006313A (es) *	2008-12-15	2011-09-27	Zealand Pharma As	Analogos de glucagon.
UY33462A (es) *	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
KR20240110072A (ko)	2011-05-18	2024-07-12	메더리스 다이어비티즈, 엘엘씨	인슐린 저항성에 대한 개선된 펩티드 제약
CA2872315A1 (fr)	2012-05-03	2013-11-07	Zealand Pharma A/S	Analogues du glucagon-like peptide 2 (glp-2)

2013
- 2013-05-03 CA CA2872315A patent/CA2872315A1/fr not_active Abandoned
- 2013-05-03 CN CN201380029907.4A patent/CN104540850B/zh not_active Expired - Fee Related
- 2013-05-03 WO PCT/EP2013/059320 patent/WO2013164484A1/fr not_active Ceased
- 2013-05-03 EA EA201491934A patent/EA028929B1/ru not_active IP Right Cessation
- 2013-05-03 TR TR2018/02689T patent/TR201802689T4/tr unknown
- 2013-05-03 JP JP2015509462A patent/JP6298044B2/ja not_active Expired - Fee Related
- 2013-05-03 AU AU2013255752A patent/AU2013255752B2/en not_active Ceased
- 2013-05-03 MX MX2014013319A patent/MX356958B/es active IP Right Grant
- 2013-05-03 US US14/398,297 patent/US9453064B2/en active Active
- 2013-05-03 EP EP13721953.1A patent/EP2844670B1/fr active Active
- 2013-05-03 KR KR1020147033951A patent/KR20150006052A/ko not_active Abandoned
- 2013-05-03 BR BR112014027345A patent/BR112014027345A2/pt not_active Application Discontinuation
2014
- 2014-11-19 IN IN9782DEN2014 patent/IN2014DN09782A/en unknown
2016
- 2016-08-16 US US15/238,126 patent/US9969787B2/en not_active Expired - Fee Related
2018
- 2018-04-11 US US15/950,235 patent/US10253080B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA201491934A1 (ru)	2015-07-30
US9969787B2 (en)	2018-05-15
EP2844670A1 (fr)	2015-03-11
JP6298044B2 (ja)	2018-03-20
US10253080B2 (en)	2019-04-09
KR20150006052A (ko)	2015-01-15
CA2872315A1 (fr)	2013-11-07
JP2015517299A (ja)	2015-06-22
CN104540850A (zh)	2015-04-22
EP2844670B1 (fr)	2017-12-06
US20180298077A1 (en)	2018-10-18
AU2013255752A1 (en)	2014-12-18
MX356958B (es)	2018-06-20
US20150125431A1 (en)	2015-05-07
EA028929B1 (ru)	2018-01-31
AU2013255752B2 (en)	2017-11-09
HK1208238A1 (en)	2016-02-26
WO2013164484A1 (fr)	2013-11-07
TR201802689T4 (tr)	2018-03-21
US20160355563A1 (en)	2016-12-08
MX2014013319A (es)	2015-07-06
US9453064B2 (en)	2016-09-27
CN104540850B (zh)	2018-05-18
BR112014027345A2 (pt)	2019-09-03

Publication	Publication Date	Title
IN2014DN09782A (fr)	2015-07-31
PH12015502042A1 (en)	2016-01-18	Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12014501702A1 (en)	2014-10-13	Imidazopyrrolidinone compounds
PH12015500115B1 (en)	2015-03-30	Glucagon analogues
IN2015DN01156A (fr)	2015-06-26
NZ709392A (en)	2016-10-28	Synergistic bacterial compositions and methods of production and use thereof
MX2011007930A (es)	2011-09-06	Conjugados de insulina cristalina.
PH12014502452A1 (en)	2015-02-02	Gip-glp-1 dual agonist compounds and methods
MX2016005556A (es)	2016-07-15	Compuestos agonistas duales de gip-glp-1 y procedimientos.
EP4406593A3 (fr)	2024-10-23	Utilisation de peptides glp-1 a action prolongee
MX356728B (es)	2018-06-12	Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2015008114A (es)	2015-11-06	Derivados de exendina-4.
MY170713A (en)	2019-08-27	Treatment protocol of diabetes type 2
PH12013502671A1 (en)	2022-04-08	Glucagon/glp-1 receptor co-agonists
MX2014015423A (es)	2015-04-09	Analogos de peptido de exedina-4.
MX2012004078A (es)	2012-07-25	Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2014008705A (es)	2015-02-05	Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX366090B (es)	2019-06-27	Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
IL235484A0 (en)	2014-12-31	Glucokinase-activating preparations for the treatment of diabetes
MX349254B (es)	2017-07-19	Compuestos para el tratamiento del sindrome metabolico.
BR112013011259A2 (pt)	2016-11-01	condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
MX2014011838A (es)	2015-03-09	Uso de neuregulina para tratar lesion de nervio periferico.
MX2016006603A (es)	2016-09-06	Compuestos piperidinicos con actividad multimodal contra el dolor.
IN2012DN00549A (fr)	2015-06-12
IN2014KN01772A (fr)	2015-10-23